# Drug-Induced Acute Kidney Injury: Student Handout

> **Updated March 2026 to reflect KDIGO 2026 draft guideline**

## Turn the medication review into a follow-up plan

For a suspected drug-related kidney change, record the exposure timeline, probable mechanism, which drug/dose changed, an alternative if needed, and the next creatinine/potassium check. Review the next maintenance dose promptly when clearance changes, distinguish it from a loading dose, and do not treat eGFR during unstable AKI as steady-state clearance. Document when and how beneficial therapy will restart after recovery. [KDIGO 2012 AKI guidance](https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf).

## Learning Objectives

By the end of this handout, you should be able to: - Recognize medications and drug classes that cause AKI - Understand distinct pathophysiologic mechanisms of drug nephrotoxicity - **Apply the KDIGO 2026 draft drug classification framework** (Function/Damage 2x2 grid) to categorize drug-induced kidney effects - Identify high-risk patient populations for medication-related AKI - Apply risk mitigation strategies for common nephrotoxic agents - Manage the “triple whammy” drug combination - Implement nephrotoxin stewardship principles and sick day protocols - Recognize when drug discontinuation is urgent

------------------------------------------------------------------------

## Overview: Medication as a Modifiable Risk Factor

Drug-induced AKI represents a **uniquely preventable cause** of kidney injury. Unlike many AKI etiologies, medication-related nephrotoxicity can often be anticipated and avoided through informed prescribing practices.

**Key Statistics:** - Medications account for 19-26% of community-onset AKI - NSAIDs: 73% increased odds of AKI in meta-analyses - PPI-associated AKI: 3.95x risk relative to non-use - Triple whammy combinations: 1.31-1.82x increased risk

------------------------------------------------------------------------

## KDIGO 2026 draft Drug Classification Framework (Figure 11)

KDIGO 2026 draft introduces a **2x2 classification grid** based on whether a drug affects kidney **Function** (GFR change) and/or causes kidney **Damage** (structural injury). This framework is essential for clinical reasoning — it determines whether a creatinine rise from a medication requires alarm or reassurance.

|  | **Damage (-)** | **Damage (+)** |
|----|----|----|
| **Function (-)** — SCr rises | **Creatinine secretion effects:** Trimethoprim, cimetidine and some other medicines can raise serum creatinine without an equivalent fall in GFR. Compare timing, magnitude, potassium, urine output and other findings; these patients can also have true AKI. Cystatin C may help with discordance. Do not automatically stop or automatically continue solely from the drug name. | **Aminoglycosides, Acyclovir, Cisplatin** — Tubular damage is occurring BEFORE SCr rises. By the time creatinine increases, significant structural injury has already happened. Early biomarkers (KIM-1, NGAL) may detect injury before SCr. |
| **Function (+)** — GFR changes | **ACEi, ARB, SGLT2i** — Hemodynamic GFR reduction without structural injury. The creatinine rise reflects altered glomerular hemodynamics, NOT nephron destruction. Usually reversible on discontinuation. Often intentional and therapeutic (e.g., SGLT2i “dip”). | **NSAIDs (prolonged use), Calcineurin inhibitors** — Both hemodynamic AND structural injury. Reduced GFR from hemodynamic effects plus direct tubular/interstitial damage. Most dangerous category — dual mechanism compounds injury. |

**Clinical interpretation:** A creatinine rise on trimethoprim can reflect secretion inhibition, but progressive dysfunction, hyperkalemia or oliguria still needs evaluation. Creatinine may lag tubular injury. SGLT2 therapy can cause an initial reversible **eGFR dip/creatinine rise**; a progressive or large change warrants a perfusion, medication and AKI assessment. NSAIDs can cause hemodynamic and structural injury.

------------------------------------------------------------------------

## The Major Categories: Mechanisms and Clinical Features

### NSAIDs: The Hemodynamic Story

**Pathophysiology:** NSAIDs inhibit prostaglandin E2 and prostacyclin synthesis in the kidney through COX-1 and COX-2 inhibition.

**Why Kidneys Are Vulnerable:** - Prostaglandins cause afferent arteriolar vasodilation - In states of reduced effective circulating volume, prostaglandins maintain glomerular perfusion - NSAID use eliminates this compensatory mechanism

**Mechanism of Injury:** 1. **Hemodynamic ATN** (most common): Sudden reduction in GFR without tubular epithelial necrosis 2. **Acute interstitial nephritis** (less common): Idiopathic immune reaction

**High-Risk Populations (Classic “KIDNEY DISASTER” Patients):** - **K**idney disease (baseline CKD) - **I**ntravascular volume depletion - **D**iabetes mellitus - **N**SAIDs (obviously!) - **E**lderly patients (age \>65) - **Y**-shaped concern: renal artery stenosis/renal disease

- **D**iuretics use (triple whammy component)
- **I**njury prevention: ACE/ARB use (triple whammy component)
- **S**evere heart failure
- **A**lbumin level low (\<3.0 g/dL, nephrotic syndrome)
- **S**ystemic illness (sepsis, cirrhosis)
- **T**ransient renal dysfunction
- **E**levated creatinine (baseline CKD)
- **R**enal hypoperfusion (any cause)

**Clinical Presentation:** - Acute oliguria or reduced urine output - Serum creatinine elevation within 24-48 hours of NSAID initiation - Usually reversible if NSAID discontinued promptly - Can progress to dialysis-requiring AKI if unrecognized

**Key Lab Findings:** - FENa \<1% (hemodynamic mechanism, preserved tubular function) - Bland urinalysis (or sterile pyuria if AIN) - Urine osmolality \>400 mOsm/kg

**Clinical Pearl:** NSAIDs are most dangerous in states of reduced effective circulating volume—heart failure, cirrhosis, nephrotic syndrome, diuretic use, or dehydration.

### The “Triple Whammy”: A Particularly Dangerous Combination

**Definition:** Concurrent use of three medication classes: 1. Diuretics (reduce plasma volume) 2. Renin-angiotensin system inhibitors (ACE/ARB; reduce efferent arteriolar tone) 3. NSAIDs (reduce afferent arteriolar dilation)

**Pathophysiology:** These three agents disrupt ALL THREE mechanisms of renal autoregulation simultaneously: - Diuretics → reduced intravascular volume - RAS inhibitors → reduced efferent vasoconstriction (GFR support) - NSAIDs → reduced afferent vasodilation (GFR support)

**Risk Magnitude:** - 4.7-7.9% of primary care patients take triple whammy combinations - Current triple whammy use: 1.31× AKI risk - **Highest risk: First 30 days of triple therapy (1.82× increased risk)** - Mortality from triple whammy AKI: ~10% in some series

**Clinical Scenarios Where This Occurs:** - Heart failure patient: on diuretics + ACE inhibitor + NSAID for pain - CKD patient: on ACE inhibitor for proteinuria + diuretic for HTN + NSAID for arthritis - Elderly patient: multiple providers prescribing independently

**Prevention Strategy:** **ALWAYS check for this combination.** If present, counsel patient extensively on warning signs and consider alternative analgesics.

### Proton Pump Inhibitors (PPIs): Acute Interstitial Nephritis

**Association:** PPIs are the **second most common drug cause of AIN** after antibiotics (14% of drug-induced AIN cases).

**Mechanism:** Immune-mediated T-cell hypersensitivity reaction affecting tubulointerstitium.

**Clinical Presentation:** - Delayed onset: AKI develops days to weeks after PPI initiation - Usually **nonoliguric** (preserved urine output despite rising creatinine) - Fever, rash, eosinophilia present in only ~1/3 of cases - Often misattributed to other causes

**Key Laboratory Findings:** - Elevated urinary WBCs (\>5/hpf, often 13-138 cells/µL) - Mild proteinuria (\<1 g/day) - White blood cell casts (supportive but not diagnostic) - **Important:** Urine eosinophils lack diagnostic utility (poor sensitivity/specificity)

**Diagnostic Approach:** - High index of suspicion required (nonoliguric AKI + timeline match PPI initiation) - Consider novel biomarker IL-9 if available (can differentiate AIN from ATN) - Kidney biopsy if diagnosis uncertain and clinical status warrants

**Treatment Outcomes:** - Discontinue PPI immediately - Corticosteroids improve outcomes if started within 2-3 weeks - 49% complete recovery, 39% partial recovery, 12% no recovery

**Clinical Pearl:** PPI-induced AIN typically occurs in older patients after weeks of PPI exposure, contrasting with antibiotic-induced AIN (young patients, early onset).

### Aminoglycoside and Vancomycin Antibiotics

**Shared Mechanism:** Both accumulate in proximal tubular cells, causing oxidative stress and mitochondrial dysfunction.

**Aminoglycosides (Gentamicin, Tobramycin, Amikacin):**

**Characteristics:** - **Delayed onset:** AKI typically develops after 5-7 days of therapy - Dose-dependent relationship (higher doses = higher risk) - Nonoliguric in most cases - Partially reversible if caught early

**Risk Factors for Aminoglycoside AKI:** - Prolonged therapy (\>7 days) - High cumulative dose - Advanced age (\>60 years) - Pre-existing kidney disease - Concurrent nephrotoxins - Volume depletion - Liver disease

**Prevention Strategy:** - Extended-interval dosing (higher single dose, longer interval) preferred over traditional dosing - Monitor trough levels; keep therapeutic but not excessive - Ensure adequate hydration - Avoid combining with other nephrotoxins (amphotericin B, NSAIDs, vancomycin)

**Vancomycin Nephrotoxicity:**

**Modern Understanding:** - Less nephrotoxic than once thought with therapeutic drug monitoring - **Critical factor:** Maintain trough levels 15-20 µg/mL (not higher) - Trough \>20 µg/mL significantly increases AKI risk - Combination with aminoglycosides or amphotericin B increases risk substantially

**Risk Factors:** - Trough levels \>20 µg/mL - Concurrent nephrotoxins - CKD (baseline) - Sepsis (increases vancomycin AKI risk)

**Clinical Pearl:** With modern TDM (therapeutic drug monitoring), vancomycin is reasonably safe; the key is avoiding excessive trough levels.

### Amphotericin B: The Antifungal Dilemma

**Mechanism:** Direct tubular toxicity through membrane binding and pore formation.

**Problem:** Necessary for serious fungal infections but highly nephrotoxic.

**Manifestations:** - Rapid AKI within 1-2 days of initiation - Severe tubular dysfunction (renal tubular acidosis features) - Often associated with electrolyte disturbances (hypokalemia, hypomagnesemia)

**Risk Reduction Strategies:** 1. **Use liposomal formulation** (much less nephrotoxic than conventional) 2. **Adequate hydration:** Normal saline before and after infusion 3. **Avoid concurrent nephrotoxins** (especially aminoglycosides, NSAIDs) 4. **Monitor electrolytes closely** (daily if possible) 5. **Monitor kidney function** (daily creatinine, daily magnesium/potassium)

**Alternative Consideration:** Newer antifungal agents (voriconazole, posaconazole, echinocandins) often have better renal safety profiles.

------------------------------------------------------------------------

## Risk Stratification for Drug-Induced AKI

### Patient-Level Risk Factors

**Individual vulnerability increases with:** - CKD (any stage; reduced renal reserve) - Age \>60 years (altered drug metabolism, reduced baseline GFR) - Diabetes mellitus - Volume depletion or states of reduced effective circulating volume - Hepatic disease (altered drug metabolism) - Congestive heart failure - Concurrent nephrotoxic exposure - Sepsis/critical illness (increased AKI susceptibility)

### Medication-Level Risk Factors

**Intrinsic nephrotoxicity varies:** - Dose-dependent: Higher doses → higher risk - Duration-dependent: Longer therapy → higher risk - Some agents specifically affect certain populations (e.g., tenofovir in older patients) - Drug interactions: Altered metabolism affecting renal exposure

------------------------------------------------------------------------

## Clinical Management Strategies

### Risk Assessment Before Prescribing

**Key Questions:** 1. Is this medication necessary? Are alternatives available? 2. Does the patient have risk factors for drug-induced AKI? 3. What’s the mechanism of toxicity? (Hemodynamic vs. toxic vs. immune) 4. What monitoring will be required? 5. What are warning signs?

### Minimizing Risk

**For NSAID-Like Analgesics:** - Use lowest effective dose for shortest duration - Avoid if possible in CKD stages 3-5 - Never use in “triple whammy” combinations - Consider topical NSAIDs (diclofenac gel) if musculoskeletal pain—only 1-2% systemic absorption - Alternative: acetaminophen, opioids (with caution), physical therapy

**For Antibiotics:** - Adjust doses for renal function using nomograms - Monitor renal function during therapy - Avoid combining nephrotoxic agents (e.g., gentamicin + vancomycin) - Use shorter courses when clinically appropriate

**For Amphotericin B:** - Use liposomal formulation when possible - Prehydrate with normal saline (500 mL before infusion) - Post-infusion hydration (250-500 mL) - Daily magnesium and potassium supplementation - Daily electrolyte and creatinine monitoring

### Ongoing Monitoring

**Baseline Assessment:** - Serum creatinine and eGFR - Urinalysis - Electrolytes (especially K+, Mg2+, Ca2+) - Relevant drug levels (vancomycin trough, gentamicin peak/trough)

**During Therapy:** - Renal function: every 2-3 days for high-risk agents - Electrolytes: daily for amphotericin B; every 2-3 days for others - Drug levels as indicated (vancomycin, aminoglycosides) - Urinalysis if symptoms develop

**Red Flags for Discontinuation:** - Rising creatinine (\>30% increase) despite dose adjustment - Oliguria - Electrolyte abnormalities resistant to supplementation - Signs of interstitial nephritis (fever, rash, eosinophilia) - Severe tubular dysfunction manifestations (RTA, hypokalemia refractory to repletion)

**Clinical Pearl:** When in doubt, discontinue the suspected agent. Many drug-induced AKIs reverse completely if caught early.

------------------------------------------------------------------------

## Nephrotoxin Stewardship (KDIGO 2026 draft Rec 4.2.1, Grade 1C)

**Concept:** Nephrotoxin stewardship is the systematic, institution-level approach to preventing drug-induced AKI — analogous to antimicrobial stewardship for infection.

**KDIGO 2026 draft recommends a multimodal approach:** 1. **Identify at-risk patients** — CKD, AKI, volume depletion, critical illness, elderly, multiple nephrotoxins 2. **Audit nephrotoxin exposure** — automated pharmacy review of concurrent nephrotoxic agents 3. **Reduce unnecessary nephrotoxin exposure** — substitute less toxic alternatives when possible 4. **Dose-adjust for kidney function** — real-time pharmacist-driven renal dosing 5. **Monitor kidney function during nephrotoxin exposure** — protocolized creatinine checks

**Clinical Decision Support Systems (CDSS) — Practice Point 4.3.2:** - KDIGO 2026 draft endorses CDSS (electronic alerts, order sets, pharmacist triggers) as a key implementation tool - Best evidence: automated alerts for triple whammy combinations, aminoglycoside duration limits, contrast exposure in AKI - CDSS reduces nephrotoxin-associated AKI by 15-25% in published implementations - Alert fatigue is real — design targeted, high-specificity alerts rather than blanket warnings

### Drug-Drug Interaction Surveillance (Practice Point 4.2.3)

**Key nephrotoxic drug interactions to monitor:** - **Aminoglycoside + vancomycin** — synergistic tubular toxicity - **ACEi/ARB + potassium-sparing diuretic + NSAID** — triple whammy plus hyperkalemia - **Methotrexate + NSAID** — NSAID reduces methotrexate clearance, causing toxicity - **Lithium + ACEi/ARB or diuretic** — reduced lithium clearance, toxicity - **Calcineurin inhibitor + azole antifungal** — increased CNI levels via CYP3A4 inhibition

**Practical application:** When admitting a patient with AKI, perform a full medication reconciliation with specific attention to nephrotoxic combinations. This is not just pharmacy’s job — the ordering clinician owns this.

### IV Hydration for Crystalline Nephropathies (Practice Point 4.2.4)

Certain medications precipitate in renal tubules as crystals, causing obstructive intratubular injury: - **Acyclovir/valacyclovir** — most common cause of crystalline nephropathy - **Methotrexate** — especially at high doses - **Sulfadiazine** — in toxoplasmosis treatment - **Indinavir** — historical, now uncommon

**Prevention:** IV hydration to maintain high urine flow rate (target urine output \>200 mL/hr during high-risk infusions). Alkalinization of urine may help for methotrexate and sulfonamides.

------------------------------------------------------------------------

## Sick Day Protocols (KDIGO 2026 draft Rec 4.11.1, Grade 2D)

**Concept:** Patients on chronic medications that affect kidney function should be educated to **temporarily stop** specific drugs during acute illness (fever, vomiting, diarrhea, dehydration, reduced oral intake) to prevent AKI.

**Medications to STOP during acute illness (“Sick Day Drugs”):**

| Drug Class | Why Stop | Restart When |
|----|----|----|
| **ACEi / ARB** | Hemodynamic GFR dependence — reduced perfusion during illness causes AKI | Eating/drinking normally for 24-48 hours; stable creatinine |
| **Diuretics** | Compound volume depletion during illness | Volume status restored; able to maintain oral hydration |
| **Metformin** | Lactic acidosis risk if GFR drops acutely | Eating normally; confirm creatinine stable |
| **NSAIDs** | Afferent arteriolar constriction compounds hypovolemia | Illness resolved; adequate hydration |
| **SGLT2 inhibitors** | Volume depletion + euglycemic DKA risk during illness | Eating/drinking normally for 24-48 hours |

**Critical requirement — the RESTART PLAN:** - Stopping medications is only half the protocol. **Every sick day plan MUST include a documented restart plan.** - Patients who stop ACEi/ARB during illness and never restart have worse long-term cardiovascular and kidney outcomes - The restart trigger: resumption of normal oral intake for 24-48 hours with stable or improving symptoms - Document the restart plan in the patient’s after-visit summary or discharge instructions - Schedule a follow-up creatinine 1-2 weeks after restart

**Patient education:** Provide written sick day rules at every visit where these medications are prescribed. Verbal instructions alone are insufficient — patients forget during acute illness.

------------------------------------------------------------------------

## Special Population: PPI-Induced Chronic Kidney Disease?

**Controversial Area:** Large observational studies link PPIs to CKD progression, but causation remains unproven.

**What We Know:** - PPIs are associated with AIN (well-established, immune-mediated) - Chronic PPI use shows association with CKD in observational studies - Possible mechanism: repeated subclinical AIN episodes leading to fibrosis - COMPASS trial (large RCT): 0.27 mL/min faster GFR decline with pantoprazole vs. placebo

**Clinical Guidance:** - PPI use appropriate for clear indications (GERD, H. pylori, NSAID prophylaxis) - Deprescribe when indication no longer clear - Annual kidney function monitoring reasonable in patients on long-term PPI - Don’t withhold PPIs for appropriate indications, but review necessity regularly

------------------------------------------------------------------------

## Table: Drug-Induced AKI at a Glance

| Drug Class | Mechanism | Onset | Reversibility | Monitoring | Prevention |
|----|----|----|----|----|----|
| NSAIDs | Hemodynamic ATN or AIN | 24-48 hrs | Reversible if early | Cr, UA q2-3d | Avoid in volume depletion; triple whammy screen |
| PPIs | Immune-mediated AIN | Days-weeks | 50% complete recovery | Cr q1-2w | Limit duration; review necessity |
| Aminoglycosides | Oxidative, tubular | 5-7 days | Partially reversible | Cr, levels daily | Extended-interval dosing; avoid combos |
| Vancomycin | Oxidative, tubular | 3-5 days | Reversible if TDM | Trough level, Cr daily | Keep trough 15-20 µg/mL |
| Amphotericin B | Direct tubular | 1-2 days | Variable | K+, Mg2+, Cr daily | Use liposomal form; prehydrate |
| Cisplatin | Oxidative, tubular | 2-5 days | Rarely reversible | Cr, UA, KIM-1 | Aggressive hydration; dose-space |

------------------------------------------------------------------------

## Practice Questions

**Question 1:** A 74-year-old with CKD Stage 3b (eGFR 42), hypertension (on lisinopril), and osteoarthritis presents for pain management. She’s also on furosemide for fluid management. Which medication choice would carry the LOWEST nephrotoxicity risk? A) Ibuprofen 600 mg three times daily B) Diclofenac gel applied locally to painful joints C) Naproxen 500 mg twice daily D) Indomethacin 50 mg daily

**Answer:** B) Diclofenac gel applied locally to painful joints. This patient has classic “triple whammy” risk factors: CKD, ACE inhibitor (lisinopril), and diuretic (furosemide). Oral NSAIDs would be contraindicated. Topical diclofenac has only 1-2% systemic absorption, making it safe even in this setting. Options A, C, and D are all oral NSAIDs that would pose significant triple whammy risk.

------------------------------------------------------------------------

**Question 2:** A 56-year-old with normal baseline renal function develops AKI (creatinine 2.1, was 0.9) on day 9 of vancomycin therapy for MRSA bacteremia. Vancomycin trough is 28 µg/mL. Urinalysis shows muddy brown casts. Which is the most appropriate next step? A) Continue vancomycin; AKI is prerenal from sepsis B) Increase vancomycin dose to improve MRSA coverage C) Decrease vancomycin dose; adjust dosing interval to maintain trough 15-20 µg/mL D) Discontinue vancomycin; switch to linezolid

**Answer:** C) Decrease vancomycin dose; adjust dosing interval to maintain trough 15-20 µg/mL. The combination of high trough (28 µg/mL) and muddy brown casts indicates vancomycin-induced ATN. The trough is excessive and likely causing toxicity. Reducing dose while maintaining therapeutic trough (15-20 µg/mL) allows continued MRSA coverage while reducing nephrotoxicity. Linezolid might be considered if AKI worsens despite dosing adjustment, but optimization of vancomycin dosing should be first-line.

------------------------------------------------------------------------

**Question 3:** A 68-year-old with CKD Stage 4 (eGFR 28) and heart failure (on furosemide and lisinopril) presents with severe knee osteoarthritis pain affecting quality of life. He has tried acetaminophen and physical therapy without relief. Which approach represents best practice? A) Prescribe ibuprofen 400 mg three times daily; risk is justified for pain relief B) Prescribe high-dose topical diclofenac; risk still too high C) Counseling regarding triple whammy risk; if NSAID deemed necessary, use short-acting formulation for \<5 days maximum with close monitoring D) Prescribe opioids; NSAIDs completely contraindicated in his situation

**Answer:** C) Counseling regarding triple whammy risk; if NSAID deemed necessary, use short-acting formulation for \<5 days maximum with close monitoring. This represents evidence-based individualized risk-benefit assessment. The patient has clear indications (severe pain affecting QOL) but high risk (CKD Stage 4 + diuretic + ACE inhibitor). Short-term (≤5 days), low-dose NSAID use with close monitoring may be acceptable in selected CKD patients when benefits clearly outweigh risks. This requires shared decision-making with the patient and baseline + follow-up lab work. Option A (continuing current agents long-term) would be inappropriate; option B might be safer but still carries triple whammy risk; option D ignores potential NSAID benefits.

------------------------------------------------------------------------

## Key Takeaways

1.  **Drug-induced AKI is preventable** — medication review before prescribing is critical
2.  **Use the KDIGO 2026 draft Function/Damage grid** — not all creatinine rises mean injury (trimethoprim, SGLT2i dip); some injuries occur before creatinine rises (aminoglycosides)
3.  **The triple whammy** (diuretics + RAS inhibitors + NSAIDs) is particularly dangerous, especially in first 30 days
4.  **Mechanism matters:** Hemodynamic vs. toxic vs. immune-mediated require different management
5.  **Nephrotoxin stewardship is a systems approach** — CDSS, pharmacy alerts, and protocolized monitoring reduce AKI (Rec 4.2.1)
6.  **Timing is key:** Early discontinuation of offending agent often results in complete recovery
7.  **Sick-day planning:** Give an individualized, written hold and restart plan for relevant medicines during dehydrating or severe illness. Explain when to contact the team and arrange follow-up; do not treat all acute illnesses as an automatic instruction to stop every kidney-protective drug. KDIGO 2026 AKI/AKD guidance cited here remains a public-review draft.
8.  **Monitoring is essential:** Regular Cr, UA, and drug levels prevent catastrophic progression
9.  **Risk stratification guides decisions:** Patient factors (age, CKD, volume status) modify medication choice
10. **Alternatives exist** for most nephrotoxic drugs; consider them systematically

------------------------------------------------------------------------

## See Also

### Related Student Handouts

- AKI Workup and Diagnostic Approach
- Acute Interstitial Nephritis
- ATN Management
- RAAS Inhibitors and Renal Protection
- Diuretics

### Clinical Content (01-Clinical-Medicine/Nephrology)

- AKI Hub - Full Clinical Reference
- Essential Renal Laboratory Tests

### Butler-COM Resources

- Butler COM - Nephrology Deep Dive

------------------------------------------------------------------------

## Related Resources

- NSAID Risk-Benefit Assessment in CKD
- PPI-Associated Kidney Disease
- Antibiotic Nephrotoxicity
- AKI Workup and Diagnosis

------------------------------------------------------------------------

**Document Type:** Student Handout **Level:** PA/Medical Student **Created:** 2026-02-12 **Source:** Comprehensive drug-induced AKI clinical literature, KDIGO 2026 draft AKI/AKD Guideline

### Also on this topic

The same subject at other levels of depth.

- **Clinical Mastery deep dive:** [Drug-Induced AKI: Comprehensive Overview of Mechanisms, Agents, and Management](https://urinenephrology.org/mastery/aki-advanced/drug-induced-aki-comprehensive-overview.html)


---

[Website version](https://urinenephrology.org/student-resources/aki/drug-induced-aki-student-handout.html) · Markdown synchronized October 3, 2026.